Immunic to Participate in Industry and Scientific Conferences in June

Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [2] Group 1: Company Overview - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 and phase 2 clinical trials for relapsing and progressive multiple sclerosis, showing therapeutic activity in patients with relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis [2] - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and additional anti-inflammatory and anti-viral effects by inhibiting dihydroorotate dehydrogenase (DHODH) [2] - IMU-856 targets Sirtuin 6 (SIRT6) to restore intestinal barrier function and regenerate bowel epithelium, with plans for a phase 2 clinical trial for gastrointestinal diseases like celiac disease [2] - IMU-381 is a next-generation molecule in preclinical testing aimed at addressing gastrointestinal diseases [2] Group 2: Upcoming Events - Immunic will participate in the BIO International Convention 2024 from June 3-6, where Jessica Breu will present a company overview on June 4 at 11:00 am PDT [1] - The presentation will be accessible on Immunic's website, with an archived replay available post-conference [1] - Immunic's management will engage in partnering activities at the BIO International Convention [1] - Additionally, Immunic will participate in the Pharmaceutical Contract Management Group (PCMG) Assembly 2024 from June 5-7, with Werner Gladdines participating in a panel discussion on June 6 at 12:05 pm CEST [4]